HNHyeon-Woo Nam

Hyeon-Woo Nam

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Hyeon-Woo Nam has a total of 14 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Long-Term Protective Immunity Induced by a GRA6-Containing Virus-like Particle Vaccine Against Toxoplasma gondii (ME49) Infection

    by Su In Heo, Hae-Ji Kang, Ying Piao, Hyeon-Woo Nam, Ji-Hyun Lee, Fu-Shi Quan

    Background: Virus-like particle (VLP) vaccines against Toxoplasma gondii (T. gondii) have mainly been evaluated in terms of short-term protection, with limited information available on their long-term protection. In this study, we developed a VLP vaccine displaying T. gondii dense granule protein 6 (GRA6) and evaluated its long-term protective efficacy against T. gondii ME49 challenge infection. Methods: GRA6 VLPs were generated using a recombinant baculovirus expression system and were characterized using Western blotting and transmission electron microscopy. Mice were immunized intramuscularly three times with GRA6 VLPs and after 6 months were challenged orally with ME49. Four weeks after challenge, the mice were sacrificed and protective immunity was evaluated. Results: GRA6 VLP immunization elicited sustained T. gondii-specific immunoglobulin G (IgG), IgG1, and IgG2a antibody responses, with the IgG2a isotype dominant. GRA6 VLP immunization induced antigen-specific IgG antibody-secreting cells in the spleen and bone marrow, and enhanced germinal center B cells, memory B cells, and memory CD4+ and CD8+ T-cell responses. GRA6 VLP immunization significantly reduced brain parasite burden and inflammatory cytokine levels (interferon-gamma and interleukin-6), while reducing body weight loss after ME49 challenge. Conclusions: GRA6 VLP immunization conferred sustained protection even 6 months after the final immunization, as evidenced by enhanced humoral and cellular immune responses, reduced brain parasite burden, and body weight loss. These findings support the use of GRA6 VLPs as a promising non-infectious vaccine platform for inducing long-term protective immunity and limiting parasite persistence and tissue cyst formation.

  • Open Access

    Evaluation of the Efficacy of Anthelmintic Drugs Against Trichinella spiralis Larvae

    by Soon-Ok Lee, Su In Heo, Hyeon-Woo Nam, Ji-Hyun Lee, Ki Back Chu, Gi-Ja Lee, Tong In Oh, Sung Soo Kim, Fu-Shi Quan

    Background: Albendazole, mebendazole, and ivermectin are effective against adult Trichinella spiralis but show limited efficacy against encapsulated muscle stage larvae. This limitation highlights the need for improved experimental approaches to evaluate anthelmintic activity at this stage and to identify alternative therapeutic candidates. Methods: Seven antiparasitic drugs, albendazole (ABZ), miltefosine (MLT), ivermectin (IVM), tribendimidine (TBD), praziquantel (PZQ), artesunate (ART), and mefloquine (MEQ), were evaluated for in vitro activity against T. spiralis muscle larvae. Larval viability was quantified using a tetrazolium salt XTT assay to determine IC50 values and compare with microscopic assessments. Based on in vitro activity, TBD was selected for in vivo evaluation in a mouse model, where efficacy was assessed by muscle larval burden and histopathological changes. Results: TBD, MEQ, IVM, and ABZ exhibited measurable in vitro efficacies against T. spiralis larvae, with TBD showing the lowest IC50 value at 135.2 μM. XTT formazan absorbance correlated strongly with larval number and incubation time. In vivo, TBD treatment significantly reduced larval burdens in diaphragm and gastrocnemius muscles and was associated with reduced collagen capsule thickness, inflammation, and fibrosis compared with ABZ-treated controls. Conclusions: This study validated an assay for quantitative evaluation of T. spiralis muscle larvae and demonstrates robust in vitro and in vivo activity of TBD against this stage.

  • Open Access

    Protection Against Toxoplasma gondii Lethal ME49 Challenge Induced by Influenza Virus-like Particles Containing Dense Granule Protein 14

    by Jie Mao, Hae-Ji Kang, Gi-Deok Eom, Su In Heo, Hynnu Nam, Ji-Hyun Lee, Ki-Ho Park, Mi Suk Lee, Sung Soo Kim, Fu-Shi Quan

    Background/Objectives: Toxoplasma gondii (T. gondii) dense granule antigen 14 (GRA14) is a parasitophorous vacuole membrane protein that plays a critical role in the development of chronic-stage cysts. However, its potential as a vaccine antigen and long-term immunity have not been evaluated using a virus-like particle (VLP) platform. Methods: influenza matrix protein (M1)-based VLPs displaying GRA14 were generated. Female BALB/c mice were intranasally immunized with the VLP vaccine and orally challenged with lethal ME49 cysts either 10 weeks or 32 weeks after prime vaccination for short-term and long-term immunity evaluation, respectively. Results: GRA14 VLP vaccination elicited higher levels of T. gondii-specific IgG, IgG1, and IgG2a antibody responses in sera compared to non-immunized controls. Upon challenge infection, elevated IgG- and IgA-secreting plasma cells, germinal center B cells, and memory B cells were observed, and CD4+, CD8+ T-cells, as well as both Th1 (IFN-γ) and Th2 (IL-4, IL-5) cytokines, were also increased. For the short-term immunity study, vaccinated mice exhibited suppressed cerebral inflammation, significantly reduced brain cyst burdens, maintained stable body weight, and achieved 100% survival. For the long-term study, GRA14 VLPs sustained elevated IgG and IgG1 levels as well as conferred partial yet significant protection, with lower cyst loads and 83% survival. Conclusions: GRA14 VLPs induce durable, balanced humoral and cellular immunity and provide both short-term and long-term protection against lethal chronic toxoplasmosis, supporting their potential as promising vaccine candidates.